The AAD’s new guidelines for the care and management of acne vulgaris include several updates for dermatologists, including an increased emphasis on oral antibiotic stewardship and recommendations for use.
Research shows dermatologists are overprescribing antibiotics for acne treatment, and patients and their parents seem unaware of the consequences, as well as alternatives to antibiotic treatment for acne.
Study demonstrates current antibiotic use for acne therapy far surpasses guideline recommendations and calls for dermatologists to decrease extended courses of antibiotics through early recognition of failure and guiding patients to alternative therapies.
There is an absence of strong evidence supporting the recommendation that cumulative dosing of isotretinoin follow a reference range of 120 to 150 mg/kg. This points to the need for clinicians to treat their patients to achieve clearance of acne rather than adhere to this range.
Clinicians recognize that acne is increasingly presenting in pre-adolescents and that early presentation is also a predictor of worse disease in the future and the potential for scarring. Prompt, aggressive treatment will lead to better outcomes and will reduce the potential for adverse psychosocial effects.
A new study suggests that 27% of acne patients don’t get all or even, perhaps, any of their doctor-recommended acne medications. These patients are more likely to get their medications when only one treatment is prescribed.
There is increasing interest in so-called alternative medicine. Both patients and practitioners are clearly interested in this domain and this is in striking contrast to the bright, shining edifice of evidence-based medicine.
The Food and Drug Administration has approved Onexton Gel (clindamycin phosphate and benzoyl peroxide 1.2 percent/3.75 percent, Valeant Pharmaceuticals) for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older.